Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26693436 | 0.95 | PARP1 (0.51) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL4767634 | 0.93 | PARP1 (0.50) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL26693369 | 0.90 | PARP1 (0.44) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL28580499 | 0.84 | PRKAB2 (0.48) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL21806659 | 0.83 | MKNK1 (0.46) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL38656590 | 0.80 | PRKAB2 (0.51) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL38656217 | 0.80 | PRKAB2 (0.51) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL38659922 | 0.80 | PRKAB2 (0.51) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL4045246 | 0.79 | KMT2A (0.46) | PARP1PARP2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL16401323 | 0.79 | KMT2A (0.46) | PARP1PARP2CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023222849-A1 | AMINO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222849-A1 | AMINO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20100144729-A1 | COUMARIN DERIVATIVES | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2109606-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | Novartis Ag (CH) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008092930-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144729-A1 | COUMARIN DERIVATIVES | F3, CYP3A7, CYP3A4 | PARP1 3644/4885PARP2 3443/4885PARP3 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.